Collectively, the findings derived from ECHELON-2 led to approval of BV + CHP for the frontline treatment of CD30+ PTCL, which has become a standard of care option, particulary for ALCL. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.